Preoperative neoadjuvant chemotherapy combined with radical surgery in cervical cancer

To investigate the efficacy of preoperative neoadjuvant chemotherapy combined with radical surgery on cervical cancer patients and its effect on the prognosis of patients and serum squamous cell carcinoma antigen (SCC-Ag) level.

163 patients with cervical cancer composed the research group. Among them, 72 patients treated with radical resection of cervical cancer were enrolled in the control group, while the remaining 91 patients were enrolled in the study group and treated with preoperative neoadjuvant chemotherapy combined with radical resection of cervical cancer. The clinical indicators during and after the surgery, as well as the efficacy, were compared between the two groups. Serum SCC-Ag level before and after the treatment was measured by enzyme-linked immunosorbent assay (ELISA).

The total effective rate of the study group was statistically higher than that of the control group (p<0.05). Seven cases (9.72%) of adverse reactions occurred in the control group. Thirteen cases (12.09%) of adverse reactions occurred in the study group. The serum SCC-Ag levels of the two groups after the treatment were significantly lower than those before the treatment, with a sharper decrease in the study group (p<0.05).

Preoperative neoadjuvant chemotherapy combined with radical surgery has remarkable efficacy in cervical cancer patients, and can significantly reduce serum SCC-Ag levels in patients, which is worthy of clinical promotion.